<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270359</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HL124204-01</org_study_id>
    <nct_id>NCT02270359</nct_id>
  </id_info>
  <brief_title>Research on Infarction With Open Arteries Using OCT and CMR</brief_title>
  <acronym>RIO</acronym>
  <official_title>Research on Infarction With Open Arteries Using OCT and CMR (RIO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prevalence of plaque disruption and to assess&#xD;
      the composition of disrupted plaques in patients with myocardial infarction (MI) and&#xD;
      non-obstructive coronary artery disease (CAD) using optical coherence tomography (OCT).&#xD;
      Additionally, cardiac magnetic resonance imaging (CMR) will be used to detect myocardial&#xD;
      abnormalities, which will be correlated to OCT findings to gain insight into the mechanisms&#xD;
      of MI in patients with non-obstructive coronary artery disease (i.e. &quot;open arteries&quot;).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single center, observational study, patients of both sexes with MI who are referred&#xD;
      for cath will be enrolled. Those who have no obstructive CAD on clinically indicated coronary&#xD;
      angiography, defined as no stenosis of &gt;50% in any major epicardial vessel, will undergo&#xD;
      coronary OCT just after the clinically indicated diagnostic angiogram, and CMR within 1 week,&#xD;
      typically within 72-96 hours. Participants will be followed for clinical events for at least&#xD;
      1 year. 20 fully eligble participants will be recruited at NYU Langone Medical Center and&#xD;
      Bellevue Hospital Center among a projected 200 enrolled patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of plaque disruption</measure>
    <time_frame>1 Week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence and pattern of LGE and myocardial edema Prevalence of different plaque types according to OCT Proportion of patients with identifiable MI etiology based on study testing</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Event rate in follow-up: death, MI, heart failure, stroke</measure>
    <time_frame>1 Year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>MI without obstructive CAD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MI without obstructive CAD, with OCT and CMR imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.</description>
    <arm_group_label>MI without obstructive CAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CMR</intervention_name>
    <description>Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)</description>
    <arm_group_label>MI without obstructive CAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>contrast agent, Gadolinium</intervention_name>
    <description>Gadolinium contrast will be administered during CMR</description>
    <arm_group_label>MI without obstructive CAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute ischemic symptoms compatible with diagnosis of acute coronary syndrome (ACS)&#xD;
             (chest pain or anginal equivalent symptoms at rest or new onset exertional anginal&#xD;
             equivalent symptoms)&#xD;
&#xD;
          -  Objective evidence of myocardial infarction (either or both of the following):&#xD;
             Elevation of troponin to above the laboratory upper limit of normal (ULN) or ST&#xD;
             segment elevation of ≥1mm on 2 contiguous ECG leads&#xD;
&#xD;
          -  Willing to provide informed consent and comply with all aspects of the protocol&#xD;
&#xD;
          -  Age ≥ 21 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stenosis ≥50% of any major epicardial vessel on invasive angiography, as determined by&#xD;
             the angiographer at the time of clinically ordered cardiac cath.&#xD;
&#xD;
          -  History of known obstructive CAD at angiography, including history of percutaneous&#xD;
             coronary intervention (PCI) or coronary artery bypass grafting (CABG)&#xD;
&#xD;
          -  Recent use of vasospastic agents, such as cocaine, triptans, ergot alkaloids (≤1&#xD;
             month)&#xD;
&#xD;
          -  Alternate explanation for troponin elevation, such as hypertensive urgency, acute&#xD;
             exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary&#xD;
             embolism, cardiac trauma&#xD;
&#xD;
          -  Coronary dissection apparent on angiography&#xD;
&#xD;
          -  Excessive coronary tortuosity which, in the opinion of the angiographer, increases the&#xD;
             risks of OCT&#xD;
&#xD;
          -  eGFR&lt;30 or contraindication to additional contrast needed for OCT in the opinion of&#xD;
             the angiographer or treating physician&#xD;
&#xD;
          -  Contraindication to MRI (including but not limited to MRI-incompatible metal implants&#xD;
             or foreign bodies)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Thrombolytic therapy for STEMI (qualifying event)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harmony Reynolds, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

